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WC purified a grurtl calcium-decreasing factor, which showed chymotrypsin.;ikc proteasc activity, from porcine pancreas to homogeneity, The 
factor administered to mice intravenously at a dose of 20 pdkg b.w. decreased serum calcium by 15%. Treatment of the factor with the serine 
protease inhibitor, PMSF, caused a leftward shilt in the dose-response curve, showing strengthcncd activity. It also caused a decrease in serum 
calcium and hydroxyprolinc levels in rats, At a dose of IG ngml, the factor inhibited 15Ca release from cultured fetal long bone stimulated by 
parathyroid hormone (PTH) and PTH-related protein, but not by interleukin-lu. prostaglandin E, and 1,25sdihydroxy vilamin D,. No other 
well-known pancreatic proteases had these ffects. In view of the results of experiments u ing protease inhibitor and pancreatic proteases, and in 
view of the specificity of this factor in vitro, we propose that Ihe l&tor exerts its serum calcium-decreasing activity most probably not through 
proleolytic degradation of PTH, but through an inhibition of PTH action on bones by a yet undefined mechanism. 
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1. INTRODUCTION 2. EXPERIMENTAL 
Takaoka has proposed that the porcine pancreas con- 
tains the (new) factor(s), named PX, with many biolog- 
ical activities including the reduction of serum calcium, 
amino acids and blood urea nitrogen levels, and the 
increase of leukocytes [I,2]. Acute pancreatitis accom- 
panied by hypocalcemia, which suggests that the pan- 
creas has serum calcium-controlling factor(s) [3]. We 
purified a serum calcium-decreasing factor from por- 
cine pancreas which we have named caldecrin. In this 
report we show that caldecrin has a serine protease 
activity, but that the caldecrin function is fully ex- 
pressed even after the inhibition of protease activity. 
Abbreuiu~iorw caldecrin, serum calcium-decreasing factor; TFA. 
trifluoro acetic acid; FPLC, fast-protein liquid chromatography; 
DFP, diisopropyl fluorophosphate; PMSF, phcnylmethylsulfonyl flu- 
oride; APMSF, 4.amidino-phcnyl-methancsulfonyl fluoride; E-64, L- 
rrans~3-~rboxy-oxiran-2-catb6nyl-L-lcucyla~atine; PTH, parathy- 
roid hormone; PTHrP, parathyroid hormooe related protein; IL, in- 
terleukin: PGE. prostaglandin E; l,2S(OH)zD,, 1,?5_dihydroxy vita- 
min D,; PAGE, polyacrylamide gel electrophoresis; IEF, isoelectric 
focusing, 
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2.1. Bioassay for remnt culciunt-dccreusing acrisity and Iire tneusure- 
Male balb/c mice weighing 20-30 g and male Wistar rats weighing 
60-70 g wcrc injected with 2OO~VZO g body weight of the test sample 
in 0. I M Tris-HCI (pH 7.4) into the tail vein after starvation for IS-20 
h. and were assayed tbr serum calcium and hydroxyproline concentra- 
lions 4 h after the injeclion. The calcium concentration was measured 
using the o-Xa@!phlhd!ein complexsone method [4]. The serum hy- 
droxyproline concentration was measured using an amino acid ana. 
lyrer (Hitachi type 835). 
2.2. Bloassav Jar bone resorption using lung-bmc chre 
A long-b&e organ culture was performed as described by Sato et 
al. [5]. The bone-resorption activities of hormones and test materials 
were exprL!sed as the percentage of ‘5Ca released in the culture me- 
dium of the total Ya incorporated in the bone. 
2.3. Pur$curion of scrun~ culcLn-decreasing fucfor frm; porcbtr parr- 
creus 
Acetone powder of porcine pancreas was extracted with 0. I M cold 
Tris-HCI buffer (pH 7.5) in 2% of NaCl for 1 h. After centrifugation. 
the supernalant was fractionated with acetone (30-60%), dialyrxcl 
against water and fractionated with saturated ammonium sulfate (45- 
60%). The precipitate was dissolved in 50 mM sodium acetate (pH 5.5) 
and dialyzed overnight against he same buffer. The dialyzate was 
applied to a Q Sepharose Fast-Flow (Pharmacia) ion-exchange col- 
umn (4.5 x I6 cm). After washing, the absorbed materials were eluted 
by a stepwise increase of NaCl from 0.1 to 0.5 M in the starting buffer 
at a flow rate of 5.3 ml/min, and I .5 min fractions were collected. The 
third peak at 0.2 M NaCl eiution was concentrated by precipitation 
with 80%.saturated amnonium sulfate, and :hc confentiatc ws a$- 
plied to a Superdcx 75 FPLC column (Pharrnacia), equilibrated w$h 
0.2 M ammonium acetate (pH 6.8). Tnr fraclioo: were lutd at a fiow 
rate oTO.5 ml/min and were collected every 2 min. Fractions ofmolec. 
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ular weights between 22.000 and 15,000 Da were combined. dialyzed 
against SO mM sodium acetate (pH 5.5) and then applied to a Mono 
Q FPLC column (Pharmacia). Absorbed materials were cluted on a 
NaCl gradient from 0 to 0.5 M in the starting buffer at a flow rate of 
0.5 ml/min, and 2 min fractions were collected. The fractions of the 
main peak eluted at 0.2 M NaCl from the Mono Q FPLCcolumn were 
applied to a reverse-phased HPLC column (Wakosil5C18.?00), cquil. 
ibrated with 0.1% TFA and eluted on a 25 min linear gradient of 
acetonitrile in 0.1% TFA from 0 to 50% and a S min linear gradient 
from 50 to 80%. The factor was eluted at 50% acetonitrilc. 
2.4. Other Procedirres 
SDS-PAGE was performed by tricinc-SDS-PAGE on 16.5% gels 
and stained with Coomassie brilliant blue[6]. The isoelectric point was 
determined using IEF-PAGE on 4% gels [7]. Antiscr!xn to purified 
caldecrin wns raised in female rabbits. Prolease activity was assayed 
using azocasein as a substrate [8]. 
3. RESULTS AND DISCUSSION 
We purified serum calcium-decreasing factor (calde- 
crin) from the porcine pancreas as described in section 
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Fig. 1. (A) SDSh?AGE and (E) IEF-PAGE analysis of puriffcd calde- 
crin (A, 20 ygilane: B, 14 PgIlanc). (C) SDS-PAGE and Western 
blotting analysis of extract (lane 1 and 3, 21 kdlanc) and purified 
caldecrin (lane 2 and 4, 8 ,@ane). 
2. As shown in Fig. lA, purified caldecrin treated with 
1 mM PMSF showed a main band migrating at 28,000 
Da and minor bands with smaller molecular weight on 
SDS-PAGE analysis. But on IEF-PAGE analysis, puri- 
fied caldecrin revealed one band and the pI was calcu- 
lated to be 4.5 (Fig. IB). The starting extract and puri- 
fied caldecrin were then compared by SDS-PAGE and 
Western blotting immunostained with polyclonal anti- 
body against purified caldecrin. Fig, 1C shows that only 
the major band of 28 kDa was detected with the starting 
extract. These results suggest hat the minor compo- 
nents of purified caldecrin were attributable to the deg- 
radation of caldecrin during purification. 
As shown in Fig. 2, the injection of purified caldecrin 
into mice caused a dose-dependent decrease of serum 
calcium and the effect reached a maximum decrease of 
15% at 20 pg/kg body weight. The bioactivity of calde- 
crin was almost the same as that of porcine calcitonin 
[9], but the partial amino-acid sequence of caldecrin 
showed no similarity to the calcitonin sequence (data 
not shown). Thus, the activity of purified caldecrin 
could not have resulted from calcitonin contamination. 
During the purification of caldecrin, we found that 
the appearance of some minor bands on SDS-PAGE 
analysis was suppressed by pretreatment of samples 
with protease inhibitor, PMSF. We thus measured the 
protease activity of purified caldecrin using azocasein as 
a substrate. Table I shows that the protease activity of 
caldecrin was almost completely inhibited by DFP, 
PMSF, soybean trypsin inhibitor and chymostatin, in- 
dicating that caldevrin is a chymotrypsin-like serine 
protease. The specific protease activity of caldecrin was 
37% of that of chymotrypsin. Polyclonal antibodies 
against purified caldecrin did not react with chymotryp- 
1 00 
Caldecrln admlnlstraied (ug/Kg 6.W.) 
‘P~O.05. ‘“P40.01 
Fig. 2. Dose-response curve ofcaldecrin on the serum calcium concen- 
tration and cvidcnce for calcium-decreasing activity with no relation 
to protcnsc activity. Various conccntrutions of purified ztldecd:. with- 
out (0) or with (0) pretreatment of I mM PMSF. or PMSF cr:ntrol 
vehicle aionc (13) were injected in mice. Values were expressed as mean 
ti SD. of mice (I&). 
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The effects of various inhibitors on the protease activity of the strum 
calcium-decreasing factor, caldecrin. Purified caldccrin (4 ,~g) was 
prcincubated with various protease inhibitorsat 37°C for 5 min. Then 
axocasein hydrolysis activity was measured with incubation at 37OC 
for 30 min. Values arc exnrcssed as means zk SD. of five experiments 
Table I Table II 
The effect of the serum calcium~dcoreasing factor (c&&in) on serum 
calcium and hydroxyproline l vels. Purified caldecrin or vehicle were 
injected into starved rats at a dose of I m@rg b.w. and assayed 4 h 
after injection. Values were exprcased as ittans + SD. of rata (n=S) 
Protease inhibitors 
DPP (0.1 mM) 
PMSF (I mM) 
APMSF (50 PM) 
Leupeptin (100 yM) 
Chymostatin (IO0 ruM) 
E-64 (2.5 ,uM) 
Pepstatin (100 NM) 
Soybean trrusin inhibitor (100 Wml) 
Protcolytic activity 
of caldecrin 
(% of control) 
10.6+ 0.4, 
3.12 3.4 
97.6+, 9.2 
94.4f 7.6 
12.22 3.3 
104.2? 3.7 
55.8C11.3 
1.8C 2.6 
*Protease activity prcincubatcd with DFP for IO min was complctcly 
diminished (0.5 + Lt.0296 ofcontrol), 
sin (data not shown). These results suggest hat the 
chymotrypsin-like protease activity of caldectin is not 
derived from chymotrypsin contamination. Further- 
more, purified caldecrin treated with the irreversible 
setine protease inhibitor, PMSF, still showed serum cal- 
cium-decreasing activity, the maximum activity of 
which (20% decrease) was much greater than the activ- 
ity of the untreated sample, and the dose-response 
curve shifted to the left. PMSF in the vehicle did not 
A 
100 
II 
0 1.0 10 100 
Caldecrin (ng/n;l) 
Control vehicle Cal&rin 
Serum calcium (mgdl) 
Serum hydroxyproline 
(nmoVml) 
8.59+0.38 7.83~t0.08~ 
58.0f7.8 42. Ii6.W 
l P<o.os 
**P<o,o1 
show any effect (Fig. 2). When incubated with mouse 
serum, the protease activity of caldecrin became unde- 
tectable (data not shown). These results uggest that the 
bioactivity of caldecrin is not connected with protease 
activity. 
Next, serum hydroxyproline was measured to find 
out whether caldecrin directly interacts with the bone 
tissue [lo]. Table II shows that caldecrin decreased not 
only the serum calcium concentration but also the 
serum hydroxyproline l vels in rats, suggesting that cal- 
decrin inhibits not only calcium release from the bone 
but also hydroxyproline degradation. The plasma level 
of PTH in rats was 153% of the controls 2 h after 
caldecrin administration when the calcium concentra- 
tion was 92.08, suggesting that caldecrin function is 
antagonistic to PTH action but does not act by degrad- 
1 I 
N IL-la: PGE 1 1~025 PlHrP PTH $ll; 
WI 2k 
- --* -* -* -4 -+ -+ 
Fig. 3. E&t ofoaldccrin on feta! bone resorption in primary culture. (A) Fetal long bones were cultured for 3 days in a-minimum essential medium 
including various concentrations of the factor without (0) or with PTH (lo-” M) (0). Values are means -I S.D. for triplicate xperiments. (3) Frtai 
long bones were cultured with L-la (5 @ml), PGE, (20 @ml). 1.25(OH)aD, (10e9 M), PTHrP (50 ng/ml) and PTH (IO-” M) with or without 
caldecrin (10 ng/ml). Values arc means + S.D. for triplicate xperiments with two cultures. 
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Fig. 4. Effect of pancreatic protcases and caldccrin on serum calcium~decrcasing activity and PTHmblocking activity on !ong bone culture. Each 
prntease was used at a concentration of I mdkg b.w, for mouse serum calcium-decreasing activity and 10 @ml for PTH-blocking activity, 
ing PTH. Next, caldecrin was tested on an in vitro long- 
bone culture system. Although caldecrin did not influ- 
ence the basal calcium release from the bone, the release 
enhance by PTH to about 80% of the total was com- 
pletely blocked in the presence of 10 @ml of caldecrin 
(Fig. 3A). This antagonistic activity was further tested 
with other bone-resolving hormones and cytokine. The 
results showed that caldecrin specifically inhibited “Ca 
release stimulated by PTH and PTHrP, but did not 
inhibit the release stimulated by PGE, and 
1 ,25(OH),DS. This suggests possible involvement of the 
PTH receptor for the specific inhibition by caldecrin, It 
is notable that caldecrin did not inhibit the action of 
IL-la, a peptide stimulant like PTH and PTHrP. The 
bioactivity of caldecrin was not affected by PMSF treat- 
ment either, again suggesting that the antagonistic effect 
against he calcium releasing activity of the PTH family 
is not related to protease activity (Fig. 3B). While this 
study was in progress, Yoneda et al. reported that a 
partially purified porcine pancreas extract (PX) de- 
creased blood calcium in mice, and inhibited bone re- 
sorption which was not only stimulated by PTH but 
also by IL-la, PGE?, tumor necrosis factor (TNF), 
transforming rowth factor (TGF-P) and 1 ,25(OH)2Dj. 
PX also inhibited osteoclast formation [l I]. The dis- 
crepancy in antagonistic function between PX and cal- 
decrin in bone resorption may come from the difference 
in purity between the preparations. 
Finally, well-known pancreatic proteases tested were 
not effective in decreasing serum calcium and inhibiting 
280 
PTH action in long bone culture (Fig. 4), suggesting 
that caldecrin specifically counteracts PTH in bone and 
decreases the serum calcium concentration and that cal- 
decrin functions independently of proteolytic degrada- 
tion of PTH. 
Hypocalcemia is frequently observed in patients with 
acute pancreatitis [ 133. The mechanism of hypocalcemia 
in acute pancreatitis i  still unclear. One possible mech- 
anism is an abrupt release of some pancreatic alcium 
controlling factor(s) into the circulation. Only amylin in 
the pancreatic islets has been shown to have hypocalce- 
mic activity [12]. Caldecrin is different from amylin in 
molecular weight and sequence. We conclude that cal- 
decrin, a new calcium-controlling fxtor purified from 
pancreas, is a possible agent which causes hypocalcemia 
in acute pancreatitis. 
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